Research programme: sildenafil intranasal - BTG

Drug Profile

Research programme: sildenafil intranasal - BTG

Alternative Names: Sildenafil mesylate

Latest Information Update: 03 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BTG
  • Class Piperazines; Purines; Sulfones
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Erectile dysfunction

Most Recent Events

  • 03 Feb 2011 Discontinued - Preclinical for Erectile dysfunction in United Kingdom (Intranasal)
  • 04 May 2007 Intranasal sildenafil is available for licensing worldwide (http:www.btgplc.com)
  • 23 Feb 2006 Preclinical trials in Erectile dysfunction in UK (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top